Abstract | Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate Aβ aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Review, we describe current knowledge on Apo-E in the CNS, with a particular emphasis on the clinical and pathological features associated with carriers of different Apo-E isoforms. We also discuss Aβ-dependent and Aβ-independent mechanisms that link Apo-E4 status with AD risk, and consider how to design effective strategies for AD therapy by targeting Apo-E.
Introduction
Alzheimer disease (AD) is a progressive neuro degen erative disease associated with cognitive decline, and is the most common form of dementia in the elderly. Approximately 13% of people over the age of 65 years and 45% over the age of 85 years are estimated to have AD. 1 Mounting evidence from genetic, pathological, and functional studies has shown that an imbalance between production and clearance of amyloidβ (Aβ) peptides in the brain results in accumulation and aggregation of Aβ. Aggregates of toxic Aβ in the form of soluble Aβ oligomers, intraneuronal Aβ, and amyloid plaques injure synapses and ultimately cause neurodegeneration and dementia. 2, 3 The toxicity of Aβ seems to depend on the presence of microtubuleassociated protein tau, 4 the hyperphosphorylated forms of which aggregate and deposit in AD brains as neurofibrillary tangles. Aβ is com posed of 40 or 42 amino acids and is generated through proteolytic cleavage of amyloid precursor protein (APP). 5 Earlyonset, familial AD-which typically develops before the age of 65 years and accounts for only a small proportion (<1%) of AD cases 2, 3 -is primarily caused by overproduction of Aβ owing to mutations in either the APP gene or in genes encoding presenilin 1 (PSEN1) or presenilin 2 (PSEN2), which are essential components of the γsecretase complexes responsible for cleavage and release of Aβ. The majority of AD cases occur late in life (>65 years) and are commonly referred to as lateonset AD (LOAD). Although multiple genetic and environ mental risk factors are involved in LOAD pathogenesis, overall impairment in Aβ clearance is probably a major contributor to disease development. 6 Genetically, the ε4 allele of the apolipoprotein E (APOE) gene is the strong est risk factor for LOAD. [7] [8] [9] The human APOE gene exists as three polymorphic alleles-ε2, ε3 and ε4-which have a worldwide frequency of 8.4%, 77.9% and 13.7%, respectively. 10 However, the frequency of the ε4 allele is dramatically increased, to ~40%, in patients with AD. 10 ApoE regulates lipid homeostasis by mediating lipid transport from one tissue or cell type to another. 11 In peripheral tissues, ApoE is primarily produced by the liver and macrophages, and mediates cholesterol metabo lism in an isoformdependent manner. ApoE4 is associ ated with hyperlipidaemia and hypercholesterolae mia, which lead to atherosclerosis, coronary heart disease and stroke. 11, 12 In the CNS, ApoE is mainly produced by astrocytes, and transports cholesterol to neurons via ApoE receptors, which are members of the lowdensity lipoprotein receptor (LDLR) family.
indicate that ApoE isoforms differentially affect Aβ aggre gation and clearance. Several Aβindependent functions are also a ssociated with ApoE isoforms.
In this Review, we provide an overview of clinical evidence for the association between APOE genotypes and the risk of cognitive decline in AD, mild cognitive impairment (MCI) and other CNS diseases with a cog nitive component, and discuss our current understand ing of the mechanisms underlying ApoE actions and ApoEtargeted therapies.
APOE genotypes, AD and cognition APOE ε4 as a strong risk factor for AD Genomewide association studies have confirmed that the ε4 allele of APOE is the strongest genetic risk factor for AD. 16, 17 The presence of this allele is associated with increased risk of both earlyonset AD and LOAD. 18, 19 A metaanalysis of clinical and autopsybased studies demonstrated that, in white individuals, risk of AD was increased in individuals with one copy of the ε4 allele (ε2/ε4, OR 2.6; ε3/ε4, OR 3.2) or two copies (ε4/ε4, OR 14.9) compared with those with an ε3/ε3 geno type. 10 Conversely, the ε2 allele of APOE has a protective effect against AD: the risk of AD in individuals carrying APOE ε2/ε2 (OR 0.6) or ε2/ε3 (OR 0.6) is lower than in those carrying ε3/ε3. 10 In populationbased studies, the APOE ε4-AD asso ciation was weaker among African American (ε4/ε4, OR 5.7) and Hispanic (ε4/ε4, OR 2.2) populations, and was stronger in Japanese people (ε4/ε4, OR 33.1) compared with white individuals (ε4/ε4, OR 12.5).
10 APOE ε4 is asso ciated with increased prevalence of AD and lower age of onset. 7, 10, 20 The frequency of AD and mean age at clinical onset are 91% and 68 years in ε4 homo zygotes, 47% and 76 years in ε4 heterozygotes, and 20% and 84 years in ε4 noncarriers, 7, 20 indicating that APOE ε4 confers dramati cally increased risk of development of AD with an earlier age of onset in a gene dosedependent manner (Table 1) .
Genetic variants in the TOMM40 (translocase of outer mitochondrial membrane 40 homologue) gene, which lies adjacent to the APOE gene on chromosome 19, have been implicated as a modulator of AD ageofonset in APOE ε3 carriers. 21 A subsequent study, however, cast doubt on the strength of this association. 22 Whether the effects of APOE and TOMM40 on AD risk, both genetically and functional ly, are synergistic requires further investigation.
Apo-E and Aβ deposition
ApoE has an important role in Aβ metabolism ( Figure 2 ). Studies show that APOE genotypes strongly affect deposition of Aβ to form senile plaques and cause cerebral amyloid angiopathy (CAA)-two major hallmarks of amyloid pathology in AD brains. 23 Immunohistological evidence demonstrates that ApoE is codeposited in senile plaques in the brains of patients with AD. 24 Aβ deposition in the form of senile plaques is more abundant in APOE ε4 carriers than in non carriers. [25] [26] [27] The difference was most evident among individuals aged 50-59 years: 40.7% of APOE ε4 carriers had senile plaques compared with 8.2% of non carriers. 25 In individuals with positive Pittsburgh compound B (PiB)PET images, which indicate fibrillar aggregates of Aβ, 28 APOE ε4 was more common than in those with negative scans (65% versus 22%) in patients with AD. 29 Fibrillar Aβ deposition is often detected in the brains of elderly, cognitively normal individuals in a manner that depends on the presence of APOE ε4, although such an association is weaker than that in patients with AD. 30 In addition, APOE ε4 carriers have lower cerebrospinal fluid (CSF) Aβ 42 levels and show more PiB binding on PET than do noncarriers, which reflect the presence of cere bral amyloid deposition and serve as potential biomarkers for AD. 31, 32 PiBpositivity can be detected in cognitively normal APOE ε4 carriers at about 56 years of age, com pared with around 76 years of age in non carriers. 33 This difference suggests that APOE ε4 probably increases the risk of AD by initiating and accelerating Aβ accumula tion, aggregation and deposition in the brain. Although APOE ε2 reduces the risk of dementia, 34 both the ε2 and ε4 alleles of APOE increase amyloid burden compared with APOE ε3 in individuals older than 90 years, sug gesting that the protective effects of APOE ε2 against AD might not be associated with Aβ deposition.
Key points
■ The ε4 allele of the apolipoprotein E (APOE) gene is the main genetic risk factor for Alzheimer disease (AD) ■ APOE ε4 carriers have enhanced AD pathology, accelerated age-dependent cognitive decline and worse memory performance than do noncarriers ■ Numerous structural and functional brain changes associated with AD pathogenesis are detected in APOE ε4 carriers before clinical symptoms become evident ■ Apo-E affects amyloid-β (Aβ) clearance, aggregation and deposition in an isoform-dependent manner ■ Apo-E4 also contributes to AD pathogenesis by Aβ-independent mechanisms that involve synaptic plasticity, cholesterol homeostasis, neurovascular functions, and neuroinflammation ■ Apo-E-targeted AD therapy should focus on restoration of the physiological function of Apo-E through increased expression and lipidation, and inhibition of the detrimental effects of Apo-E4 Figure 1 | APOE ε4 is a major genetic risk factor for AD. The Apo-E2, E3, and E4 isoforms, which are encoded by the ε2, ε3 and ε4 alleles of the APOE gene, respectively, differ from one another at amino acid residues 112 and/or 158 (grey circles). Apo-E has two structural domains: the N-terminal domain, which contains the receptor-binding region (residues [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] , and the C-terminal domain, which contains the lipid-binding region (residues 244-272); the two domains are joined by a hinge region. A meta-analysis demonstrated a significant association between the ε4 allele of APOE and AD. 10 Abbreviations: AD, Alzheimer disease; Apo-E, apolipoprotein E. APOE ε4 also shows an association with CAA and CAArelated haemorrhages. 35, 36 CAA refers to the pathological condition in which amyloid spreads and deposits throughout the cerebral blood vessel walls, 37 and is frequently detected in AD. 23 Interestingly, although APOE ε2 is protective against AD, it is a risk factor for CAArelated haemorrhage, independently of AD, possibly by p redisposing vessels to vasculopathic complication s of CAA. 36 Prediction of AD in MCI MCI is a transitional stage between normal ageing and dementia, and is associated with increased risk of AD. 38 The rate at which patients with amnesic MCI (aMCI) progress to clinically diagnosable AD is 10-15% per year, in contrast to a rate of 1-2% per year among healthy elderly individuals. 39 The prevalence of APOE ε4 is sub stantially higher in both aMCI and dysexecutive MCI than in control individuals. 40 Patients with MCI who harbour APOE ε4 exhibit distinct cognitive profiles, which seem to resemble those of patients in the early stages of AD. 41 A case-control study reported poorer memory performance among patients with MCI who were carriers of APOE ε4 compared with noncarriers. 42 APOE ε4 is associated with impaired memory perfor mance and increased risk of memory decline in middle aged (40-59 years) and elderly (60-85 years) people with MCI. 43, 44 Furthermore, patients with MCI who are carriers of APOE ε4 experience morerapid decline in several cognitive and functional domains, and severity of the deficits is strongly associated with the APOE ε4 gene dose. 41, 45, 46 Importantly, the presence of APOE ε4 is associ ated with increased risk of progression from MCI to ADtype dementia. [47] [48] [49] Among individuals with aMCI, APOE ε4 carriers tend to be younger than non carriers, consistent with younger age of AD onset in indivi duals with APOE ε4. 50 These findings indicate that the APOE ε4 genotype in patients with MCI can serve as a predic tive factor for determination of clinical outcome and the risk of conversion to AD.
In patients with MCI, the adverse effects of APOE ε4 on cognitive functions correlate with the severity of neuro nal pathology. Those who are carriers of APOE ε4 have lower CSF Aβ 42 levels, higher tau levels and greater brain atrophy than do noncarriers. 50 Furthermore, patients with MCI who are PiBpositive are more likely to be APOE ε4 carriers and exhibit worse memory perfor mance than are PiBnegative patients. 51 Other finding suggest, although not without controversy, 52 that APOE ε4 has considerable deleterious effects on memory performance 42 and might be used to predict disease progression in combination with AD b iomarkers and n euroimaging approaches. 53 Predicting cognitive decline in healthy cases Healthy APOE ε4 carriers not diagnosed with MCI or AD show accelerated longitudinal decline in memory tests, which starts around the age of 55-60 years, revealing a possible preMCI state in this genetic subset of indivi duals. 54, 55 This memory decline, despite ongoing normal clinical status, suggests that pathological changes in AD might manifest in the brain as early as the sixth decade of life. 56, 57 Thus, APOE ε4 is associated with cogni tive decline many years before cognitive impairment becomes clinically apparent. 56, 58 Interestingly, APOE ε4 has differential effects on memory performance depend ing on age. Some studies in young adults and children have found evidence of better cognitive performance in APOE ε4 carriers than in noncarriers, which could suggest antagonistic pleiotropy, [59] [60] [61] in which APOE ε4 might offer benefits during development and early adult hood at the expense of morerapid decline in cognitive function with ageing. 62 Similar to the situation in patients with MCI, APOE ε4 is associated with enhanced amyloid pathology in cognitively normal people. The proportion of PiBpositive indivi duals follows a strong APOE alleledependent pattern (ε4 > ε3 > ε2), 25, 63, 64 and APOE ε4 increases the amount of amyloid deposition in a genedosedependent manner. 30 
APOE ε4 and other AD risk factors
The APOE ε4 genotype combines synergistically with athero sclerosis, peripheral vascular disease, and type 2 diabetes in contributing to an increased risk of AD. 65, 66 APOE ε4 is a risk factor for cardiovascular disease, sug gesting that this allele and cerebrovascular disease might have compounding effects on cognitive decline in AD. 67 Diabetes also increases the risk of AD, and the association is particularly strong among APOE ε4 car riers. 66, 68, 69 Patients with diabetes who are carriers of APOE ε4 have more neuritic plaques, neurofibrillary tan gles and CAA than do noncarriers. 66 The combina tion of a diabetesrelated factor-that is, hyper glycaemia, hyper insulinaemia, and insulin resistance-and the APOE ε4 allele promotes neuritic plaque formation. 69 APOE ε4 seems to modify the risk of AD in patients with diabetes-a disease that directly or indirectly causes vas cular and neuronal damage and further exacerbates AD pathology. Furthermore, recent research demonstrated that, independently of Aβ, ApoE4 triggers inflammatory cascades that cause neurovascular dysfunction, includ ing blood-brain barrier breakdown, leakage of blood derived toxic proteins into the brain and reduction in the length of small vessels. 70 This result suggests that ApoE4 associated damage to vascular systems in the brain could have a key role in AD pathogenesis.
APOE and traumatic brain injury
Increasing evidence has shown that APOE ε4 is associated with poorer outcomes following traumatic brain injury (TBI) compared with APOE ε2 and ε3 alleles, regardless of the severity of initial injury. 71 A meta analysis demon strated that the outcome of TBI at 6 months after injury is worse in APOE ε4 carriers than in noncarriers. 72 TBI is associated with increased risk of AD, 73 and such a risk is more evident in patients with APOE ε4. 74 Only 10% of APOE ε4 noncarriers with TBI have Aβ plaque pathol ogy, whereas 35% and 100% of TBI patients with one or two APOE ε4 alleles, respectively, possess Aβ pathology. 75 The poorer outcomes associated with ApoE4 might relate to the reduced ability of this isoform to repair and remodel synapses and protect neurons upon injury compared with ApoE3. 8 These possibilities are currently under investigation.
APOE and vascular diseases
Vascular cognitive impairment, which comprises clini cal conditions with cerebrovasculaturederived cognitive disturbances including vascular dementia, is observed in approximately 8-15% of aged individuals with cogni tive dysfunction in Western clinicbased series. 76 A recent metaanalysis has shown evidence of increased risk of vascular dementia in individuals with APOE ε4 com pared with APOE ε3 (OR 1.72). 77 Several studies suggest that the contribution of APOE ε4 to risk of vascu lar cognitive impairment is independent of other vascu lar risk factors including hypertension, dyslipidaemia and atherogenesis, 78 whereas another report shows that agerelated cognitive decline among APOE ε4 carriers is induced by brain damage owing to increased blood pressure. 79 In addition, APOE ε4 is associated with poor outcome after subarachnoid haemorrhage, 80 and is a strong risk factor for CAArelated intracranial haemor rhage. 81 These results suggest that APOE ε4 is closely associated with neurovascular dysfunctions.
APOE and other types of dementia Lewy body disease is thought to be the second most common form of dementia, and comprises a spec trum of diseases that includes Parkinson disease (PD), PDassociated dementia, and dementia with Lewy bodies (DLB). Clinical and pathological features of PD and AD frequently overlap. Most studies, however, have failed to report associations between APOE ε4 and susceptibility to PD and PDassociated dementia. 82, 83 DLB also shares clini cal and pathological charac teristics with AD and PD, 84 and several reports have shown that APOE ε4 increases risk of DLB. 85 Immuno histochemical analysis showed that deposition of Lewy bodies in patients with DLB who are APOE ε4 carriers is substantially more abundant than in those who are non carriers. 86 As Lewy bodies are considerably increased in the cerebral cortex of DLB patients with Aβ deposi tion, 87 the strong association between amyloid pathology and the pathology of Lewy body disease could explain why APOE ε4 increases risk of DLB. APOE ε4 might also be a risk factor for fronto temporal dementia, 88 although the pathophysiological role of ApoE in this disease requires further investigation. The APOE genotypes do not seem to influence the risks of Huntington disease 89 nor am yotrophic lateral sclerosis. Apo-E is primarily synthesized by astrocytes and microglia, and is lipidated by the ABCA1 transporter, forming lipoprotein particles. Lipidated Apo-E binds soluble Aβ and facilitates Aβ uptake through cell-surface receptors, including LRP1, LDLR, and HSPG. 175, 177 Apo-E facilitates binding and internalization of soluble Aβ by glial cells, disrupts Aβ clearance at the BBB in an isoformdependent manner (Apo-E4 > Apo-E3 > Apo-E2) and influences CAA pathogenesis. Abbreviations: Aβ, amyloid-β; ABCA1, ATP-binding cassette A1; Apo-E, apolipoprotein E; BBB, blood-brain barrier; CAA, cerebral amyloid angiopathy; HSPG, heparan sulphate proteoglycan; IDE, insulin-degrading enzyme; LDLR, low-density lipoprotein receptor; LRP1, low-density lipoprotein receptor-related protein 1; LXR, liver X receptor.
Mechanisms of Apo-E isoforms in AD
APOE ε4 confers a gain of toxic functions, a loss of neuro protective functions or both in the pathogenesis of AD (Figure 3 ).
Aβ metabolism and aggregation
Studies in humans and transgenic mice showed that brain Aβ levels and amyloid plaque loads are ApoE isoformdependent (ε4 > ε3 > ε2), 30, 63, 91 suggesting an important role for ApoE in modulating Aβ metabolism, aggregation, and deposition. ApoE4 is less efficient in Aβ clearance than is ApoE3 in young and old amyloid mouse models that express human ApoE isoforms. 63 Additionally, ApoE isoforms differentially regulate cholesterol levels, which have been shown to modulate γsecretase activity and Aβ production. 92 Several studies reported an APOE genotypedependent effect on CSF and brain ApoE levels (ε4 < ε3 < ε2) in ApoEtargeted replacement (ApoETR) mice, in which the mouse Apoe gene is replaced with human APOE isoforms. 91, 93, 94 This result suggests that lower levels of total ApoE exhibited by APOE ε4 carriers might contribute to disease progression. However, whether human ApoE isoform status affects CSF and brain ApoE protein levels in healthy individuals and patients with AD remains to be established. 95, 96 ApoEknockout mice clear Aβ from the brain faster than do control mice. 97 Stimulation of liver X receptors (LXRs) 98, 99 or the retinoid X receptor (RXR) 100 facilitates Aβ clearance, probably by increasing ApoE levels and lipidation. Further investigation is needed to determine whether ApoE levels are directly associated with Aβ clear ance. In addition, a recent study showed that lack of one copy of ATPbinding cassette transporter A1 (ABCA1), which shuttles lipids to ApoE, impairs Aβ clearance and exacerbates amyloid deposition and memory deficits in ApoE4TR mice, but not in ApoE3TR mice. 101 This result suggests that ApoE isoforms exhibit differential lipidation status, which affects Aβ clearance in an isoform dependent manner. Alternatively, ApoE-lipoprotein parti cles may sequester Aβ and promote cellular uptake and degradation of ApoE-Aβ complexes.
102
ApoE4-lipoproteins bind Aβ with lower affin ity than do ApoE3-lipoproteins, 103 suggesting that ApoE4 might be less efficient in mediating Aβ clear ance. In addition, ApoE might modulate Aβ removal from the brain to the systemic circulation by transport ing Aβ across the blood-brain barrier. In this respect, ApoE impedes Aβ clearance at the blood-brain barrier in an isoformspecific fashion (ApoE4 > ApoE3 and ApoE2). 104 Finally, studies in microglia have shown that ApoE3 promotes enzymemediated degradation of Aβ more efficiently than does ApoE4. 105 Together, these studies suggest that ApoE4 inhibits Aβ clearance and/ or is less efficient in mediating Aβ clearance compared with ApoE3 and ApoE2.
ApoE also seems to regulate Aβ aggregation and deposition. An important study showed that deletion of the mouse Apoe gene essentially eliminates deposition of fibrillar Aβ in amyloid mouse models. 106 Given that ApoE is codeposited with Aβ in human AD brains, 24 it is possible that ApoE promotes Aβ aggregation and deposi tion in an isoformdependent manner. The exact mecha nisms by which ApoE isoforms differentially regulate Aβ aggregation and deposition require further investigation.
Brain activity and atrophy AD is associated with both functional abnormalities of the hippocampus and cortical atrophy in the memory network. 107, 108 Patients with AD or MCI who are APOE ε4 carriers exhibit greater medial temporal lobe atrophy, particularly in the hippocampal area. 41, 109, 110 Structural MRI studies found that, compared with noncarriers, APOE ε4 carriers have accelerated agerelated reduction in cortical thickness and hippocampal volume that are tightly coupled to decline in cognitive performance. [111] [112] [113] Functional MRI (fMRI) studies reported that ApoE4 disrupts restingstate fMRI connectivity and the balance between brain networks, in the absence of amyloid pathology. 114, 115 Furthermore, cognitively normal APOE ε4 carriers have elevated rest ingstate activity in the default mode network-a network that is preferen tially affected early in AD-and higher hippocampal activation during memory tasks. [116] [117] [118] Such changes have been hypothesized to represent a compensatory response by APOE ε4 carriers in which increased cognitive effort is required to achieve an equivalent level of performance to that of noncarriers. 116, 118 Elevated baseline activity in brain networks of APOE ε4 carriers could potentially contribute to increased Aβ production, as Aβ levels are regulated by neuronal activ ity. 119, 120 Interestingly, in adults who do not have demen tia, increased hippocampal activity was associated with reduced cortical thickness in the medial temporal lobe and brain regions that are vulnerable to AD pathology. 121 Studies suggested that hippocampal hyperactivity might represent impending synaptic dysfunction and incipient cognitive decline. 122 Interestingly, another study showed a reduction of posterior default mode network connec tivity in APOE ε4 carriers in cognitively normal elderly people, implying that APOE ε4 carriers exhibit more rapid decline in connectivity of this network than do noncarriers as they age. 115 18 Ffluorodeoxyglucose PET imaging, which meas ures cerebral metabolic rates of glucose as a proxy for neuro nal activity, correlates with disease progression and predicts histopathological diagnosis in AD. 123 Mounting evidence suggests that APOE ε4 carriers exhibit lower cerebral glucose metabolism. [124] [125] [126] Healthy adults with APOE ε4 show altered patterns of brain metabolism both at rest and during cognitive challenges compared with noncarriers. 126, 127 Representative studies illustra ting the association of ApoE4 isoform with altered brain metabo lism and activity, memory decline, and amyloid pathology in cognitively normal people are shown in Figure 4 . Improved understanding of the mechanisms of ApoE4related brain activity changes, brain atrophy and reduced metabolism should help to explain why ApoE4 is a risk factor for cognitive decline and AD.
Tau phosphorylation and neurotoxicity
ApoE is produced primarily by astrocytes and micro glia. Neuronal ApoE expression can, however, be induced in response to stress or injury, probably for the purpose of neuronal repair and remodelling. 128, 129 A truncated fragment of ApoE4, resulting from proteolytic cleav age of ApoE following stress or injury, increases tau hyperphosphorylation, cytoskeletal disruption and mito chondrial dysfunction. 128, 130, 131 ApoE4 also exacerbates neurotoxicity triggered by Aβ and other insults. 128, 131 A recent study showed that neurons in patients with temporal lobe epilepsy who harbour APOE ε4 are less resilient to the damaging hyperexcitability and more sus ceptible to Aβ toxicity than are those in APOE ε3 car riers, 132 suggesting that ApoE3 might confer a neuro protective advantage over ApoE4 against neuro nal stress. Interestingly, astrocytederived ApoE4 has neuro protective effects against excitotoxic injuries, whereas neuronal expression of ApoE4 promotes excito toxic cell death. This result suggests that ApoE derived from various cellular sources might exhibit different physiological and pathological activity. 133 
Lipid metabolism
Abnormal lipid metabolism is strongly related to the pathogenesis of AD. In the CNS, ApoE mediates neu ronal delivery of cholesterol, which is an essential com ponent for axonal growth, synaptic formation and remodelling-events that are crucial for learning, memory formation and neuronal repair. 134, 135 Brain cholesterol levels are substantially reduced in hippocampal and corti cal areas in patients with AD compared with agematched controls. 136 Preferential degradation of ApoE4 relative to ApoE3 in astrocytes in transgenic animals has been pro posed to result in low levels of ApoE in the brain and CSF and reduced capacity for neuronal delivery of choles terol, suggesting that low levels of total ApoE exhibited by APOE ε4 carriers may directly contribute to disease progression. 93 ApoE4 is also less efficient than ApoE3 in transporting brain cholesterol. 137 Moreover, ApoE4TR mice have abnormal cholesterol levels and impaired lipid metabolism. 138 Insufficient levels of ApoE and/or impaired ApoE function in carriers of the ε4 allele might, therefore, lead to aberrant CNS cholesterol h omeostasis and neuronal health, which contribute to AD risk.
Synaptic plasticity and spine integrity
Synaptic failure is an early pathological feature of AD. 139, 140 Increasing evidence demonstrates that ApoE iso forms differentially regulate synaptic plasticity and repair. 141, 142 In AD and healthy aged controls, APOE ε4 gene dosage correlates inversely with dendritic spine density in the hippocampus.
143 ApoE4TR mice also have lower dendritic spine density and length compared with ApoE3TR mice. 144, 145 ApoE3, but not ApoE4, prevents loss of synaptic networks induced by Aβ oligo mers. 146 ApoE isoforms also differentially regulate den dritic spines during ageing. 143, 147 The agedependence of these differences implies that the effects of ApoE iso forms on neuronal integrity might relate to increased risk of dementia in aged APOE ε4 carriers.
Reduced synaptic transmission was observed in 1monthold ApoE4TR mice compared with Apo E3TR mice, suggesting that ApoE4 may also contrib ute to functional deficits early in development, which could account for alteration of neuronal circuitry that eventually results in cognitive disorders later in life. 147 In addition, ApoE4 selectively impairs ApoE receptor trafficking and signalling, as well as glutamate receptor function and synaptic plasticity. 141 Together, these find ings suggest that the effect of APOE ε4 genotype on risk of AD might be mediated, at least in part, through direct effects on synaptic function.
Neuroinflammation
Neuroinflammation contributes to neuronal damage in the brain and is implicated in AD pathogenesis. 148 ApoE colocalizes with plaqueassociated amyloid and micro glia, suggesting a role for ApoE in the innate immune response in AD. Lack of ApoE in mice is associated with increased inflammation in response to Aβ, 149, 150 but ApoE isoforms might differently regulate the innate immune response.
151 ApoE4 seems to have pro inflammatory and/or reduced antiinflammatory func tions, which could further exacerbate AD pathology. For example, ApoE4TR mice exhibit greater inflammatory responses to lipopolysaccharide compared with Apo E3TR mice. 152 In addition, young APOE ε4 carriers show an increased inflammatory response that may relate to AD risk later in life. 153 Consistent with this notion, non steroidal antiinflammatory drugs were shown to reduce AD risk only in APOE ε4 carriers, 154 suggesting that APOE genotype might determine the effect of antiinflammatory me dications for AD.
Neurogenesis
Hippocampal neurogenesis has an important role in structural plasticity and maintenance of brain networks.
REVIEWS
Dysfunctional neurogenesis resulting from early disease manifestations could, therefore, exacerbate neuronal vul nerability to AD and contribute to memory impairment. 155 ApoE is required for maintenance of the neural stem or progenitor cell pool in the adult dentate gyrus region of the hippocampus. 156 In ApoETR mice, ApoE4 inhib its hippocampal neurogenesis by impairing maturation of hilar γaminobutyric acidcontaining interneurons, which contributes to learning and memory deficits. 157, 158 These results demonstrate an important pathological role of ApoE4 in impairment of n eurogenesis, which might contribute to AD pathogenesis.
Apo-E as a therapeutic target in AD
Most therapeutic approaches for AD target the Aβ path way. With the recent failure of clinical trials of drugs target ing solely Aβ, an urgent need exists to define new tar gets and develop alternative therapeutic strategies to treat AD. As APOE genotype determines AD risk, and ApoE has crucial roles in cognition, ApoE might offer an attractive alternative target for AD therapy. APOE genotype status could be included in clinical trial enrol ment criteria, as some therapies might be effective only in specific APOE genotypes. Here, we briefly discuss several approaches that are currently being explored (Table 2) .
APOE genotype and Aβ immunotherapy
Recent phase III trials of immunotherapy have shown that bapineuzumab, an antibody that targets the Nterminus of Aβ, prevents Aβ deposition in the brains of APOE ε4 car riers with mild or moderate AD, but not noncarriers. 159, 160 Bapineuzumab also lowers levels of phosphorylated tau in the CSF of both APOE ε4 carriers and noncarriers. 159, 160 These reports suggest that Aβ immunotherapy is useful to eliminate Aβ from the brains of patients with AD and that its effect is likely to depend on ApoE isoforms. Major adverse effects of bapineuzumab-namely, vasogenic cerebral oedema and microhaemorrhage-occur more frequently in APOE ε4 carriers than in noncarriers. 159, 160 Although bapineuzumab failed to prevent cognitive and functional decline in these clinical trials, a combination of Aβ immunotherapy and an ApoEtargeted approach might lead to moreeffective therapeutic strategies.
Prevention of cognitive decline in ε4 carriers
A prospective study of a cognitively normal cohort showed that risk of dementia in APOE ε4 carriers is nega tively associated with high education, high level of leisure activities, and absence of vascular risk factors. 161 A recent study demonstrated that physical exercise was strongly associated with reduced PiBpositivity in cognitively normal APOE ε4 carriers, 31 indica ting that a sedentary lifestyle in APOE ε4 carriers might increase the risk of amyloid deposition. Such studies indicate that high edu cation, active leisure activities and exercise, and mainte nance of vascular health could be beneficial in reducing the risk of AD and cognitive decline, p articularly in APOE ε4 carriers.
Regulation of Apo-E expression
ApoE levels in CSF and plasma tend to be lower in patients with AD than in healthy individuals, although such findings remain controversial. 162, 163 Thus, increas ing the expression of ApoE in all APOE genotypes may prevent or slow progression of AD through acceleration of Aβ metabolism and promotion of ApoE functions in lipid metabolism and synaptic support. Compounds that increase brain ApoE expression can be identified through comprehensive drug screening. Given that expression of ApoE is controlled by peroxisome proliferator activated receptorγ and LXRs (which form complexes with RXRs), 100, 164 agonists or antagonists of these nuclear recep tors are potential candidates as ApoE modulators. Indeed, recent work has demonstrated that oral administration of an RXR agonist, bexarotene, to an amyloid mouse model decreases Aβ plaque deposition and improves cognitive function in an ApoEdependent manner. 100 The LXR agonist TO901317 also increases ApoE levels in the brain, facilitates clearance of Aβ 42 , and reverses contextual memory deficit in amyloid mouse models. 98, 99 In addition to ApoE, LXRs also regulate ABCA1, which promotes cholesterol efflux. 165 Consequently, reduction of amyloid burden by the LXR agonist GW3965 depends on expression of ABCA1 in amyloid mouse models. 166 These results suggest that upregula tion of lipidated ApoE might be necessary to maximize thera peutic effects in AD. These studies did not, however, assess the effect of increasing human ApoE3 or ApoE4 specifically. Because Aβ deposition is greater in APP transgenic mice expressing mouse ApoE than in those expressing human ApoE isoforms, 167 further studies are needed to confirm the therapeutic effect of modu lating the level of human ApoE isoforms. In addition, whether increasing ApoE4 is beneficial or harmful in Blockade of Apo-E-Aβ interaction ApoE is required for deposition of Aβ fibrils in amyloid mouse models. 106 Recent studies have demonstrated that haploinsufficiency of human APOE results in significantly decreased amyloid plaque deposition in amyloid mouse models regardless of APOE isoform status. 168, 169 Thus, dis ruption of the interaction between ApoE and Aβ might reduce Aβ aggregation and deposition, and should be considered as a therapeutic approach. Aβ interacts with ApoE through amino acid residues 12-28. A synthetic peptide mimicking this sequence, Aβ1228P, reduces Aβ deposition and ameliorates memory deficits in amyloid mouse models. 170 Blocking the ApoE-Aβ interaction using Aβmimicking peptides could, therefore, be an effective approach for treatment of AD. Screening assays can also be used to identify compounds or ApoEspecific antibodies that block ApoE-Aβ interaction. These approaches should be assessed carefully because they could disrupt ApoE-lipid interactions and the associat ed beneficial functions of ApoE.
Other Apo-E-based therapeutic approaches ApoE4 is structurally different from ApoE2 and ApoE3 owing to different domain interactions, 131 and this dif ference probably contributes to ApoE4 isoformspecific harmful effects. Modification of the structure of ApoE4 to form an ApoE3like molecule might, therefore, be an interesting approach to ameliorate these harmful effects. Indeed, several molecules that bind to ApoE4 and inter fere with domain interactions between the Nterminus and Cterminus have been found. GIND25 (disulpho nate) and GIND105 (monosulphoalkyl) are good candi dates because they decrease Aβ production induced by ApoE4 to a level similar to that induced by ApoE3.
131
CB9032258 (a phthalazinone analogue) and its deriva tives disrupt ApoE4 domain interaction and restore functional activities of ApoE4 in neurons. 171 An ApoEmimetic peptide containing the receptor binding region suppresses neuronal cell death and calcium influx associated with Nmethyldaspartate exposure in vitro.
172 COG112, a chimeric peptide con taining the receptorbinding region, is also reported to improve symptoms in mouse models of multiple sclero sis 173 and sciatic nerve crush 174 through modulation of inflammatory responses. The effects of these peptides on AD pathogenesis are unknown, however, because they do not contain Aβinteracting or lipidbinding regions. 13 ApoE receptors are also potential targets for AD therapy. For example, lowdensity lipoprotein receptor related protein 1 and lowdensity lipoprotein recep tor have crucial roles in brain lipid metabolism and Aβ clearance (Figure 2) . [175] [176] [177] ApoE receptor 2 and very low density lipoprotein receptor are essential for reelin signal ling, which is important for neuronal migration during development and synaptic plasticity in adult brains. 178 Modulation of expression of these ApoE receptors in AD brains might, therefore, restore lipid homeostasis and syn aptic plasticity, and augment Aβ clearance. 8, 178 Although ApoEbased therapies are still in early stages of develop ment, they offer great promise in the fight against AD. Clinical trials to further evaluate therapeutic potential of ApoEbased strategies are needed, with an eventual goal to develop curative and/or protective treatments for AD.
Conclusions
Work summarized in this Review highlights clinical evidence for the association between APOE ε4, AD and cognitive decline. Although the presence of APOE ε4 does not necessarily entail disease development, this genetic isoform probably accelerates the rate of disease conversion and progression. In particular, the effects of APOE ε4 on brain network connectivity, memory perfor mance, and rate of cognitive decline are agedependent in patients with AD and cognitively normal indivi duals. Thus, understanding the potential pathogenic link between APOE ε4 and cognitive function might enable earlier identification of people at increased risk of AD. In combination with other putative AD biomarkers-such as MRI scans, PiBPET, and measurements of CSF Aβ and tau-APOE allele status could add predictive value to clinical diagnosis and evaluation of treatment efficacy.
Mechanistically, ApoE4 seems to increase risk of AD and cognitive decline through both Aβdependent and Aβindependent pathways. ApoE isoforms differen tially regulate Aβ production, aggregation and clearance. Independently of Aβ, ApoE4 might be less efficient than ApoE3 and ApoE2 in delivering cholesterol and essential lipids for maintenance of synaptic integrity and plasticity. In addition, ApoE is a crucial regulator of the innate immune system, with ApoE4 promoting pro inflammatory responses that could exacerbate AD pathogenesis. Finally, ApoE isoforms have differen tial roles in maintaining vascular health-roles that are crucial given that vascular pathology is strongly associ ated with AD. Elucidation of the contribution of ApoE4 to AD pathogenesis is a considerable challenge, but one that affords the potential to assist in combating AD.
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